NeuBase Therapeutics Inc expected to post a loss of 30  cents a share - Earnings Preview

NeuBase Therapeutics

09/08/2022 03:02

* NeuBase Therapeutics Inc  NBSE.OQ   NBSE.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for NeuBase
Therapeutics Inc
is for a loss of 30 cents per share. For the same quarter last
year, the company reported a loss of 29 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $11​, above​ its last closing price
of $1.30. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.24       -0.23      -0.30     Missed  -32.4
 Dec. 31 2022  -0.23       -0.23      -0.24     Missed  -4.3
 Sep. 30 2021  -0.27       -0.23      -0.21     Beat    8.7​
 Jun. 30 2021  -0.22       -0.21      -0.29     Missed  -38.1
 ​​Mar.        -0.20       -0.22      -0.24     Missed  -9.1
 31 2021                                                
 Dec. 31 2020  -0.23       -0.23      -0.18     Beat    21.7​
 Sep. 30 2020              -0.20      -0.19     Beat    4.2
 Jun. 30 2020  -0.23       -0.23      -0.18     Beat    20.6
 This summary was machine generated August 9 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated